scholarly journals Chemotherapy Drugs Based on Solid Lipid Nanoparticles for Breast Cancer Treatment

Medicina ◽  
2020 ◽  
Vol 56 (12) ◽  
pp. 694
Author(s):  
Atefeh Ashtari ◽  
Firoozeh Niazvand ◽  
Layasadat Khorsandi
Keyword(s):  
Breast Cancer ◽  
Cell Death ◽  
Cell Migration ◽  
Cell Division ◽  
Cancer Treatment ◽  
Solid Lipid Nanoparticles ◽  
Lipid Nanoparticles ◽  
Breast Cancer Treatment ◽  
Chemotherapy Drugs ◽  
Solid Lipid

Cancer is a group of diseases that include uncontrolled cell division and cell migration, as well as resistance to cell death [...]

Bombesin conjugated solid lipid nanoparticles for improved delivery of epigallocatechin gallate for breast cancer treatment

2019 ◽  
Vol 224 ◽  
pp. 104770 ◽  
Author(s):  
Rasika Radhakrishnan ◽  
Deep Pooja ◽  
Hitesh Kulhari ◽  
Sagarika Gudem ◽  
Halley Gora Ravuri ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Solid Lipid Nanoparticles ◽  
Epigallocatechin Gallate ◽  
Lipid Nanoparticles ◽  
Breast Cancer Treatment ◽  
Solid Lipid

scholarly journals Formulation and Development of Transferrin Targeted Solid Lipid Nanoparticles for Breast Cancer Therapy

2020 ◽  
Vol 11 ◽  
Author(s):  
Geeta S. Bhagwat ◽  
Rajani B. Athawale ◽  
Rajeev P. Gude ◽  
Shadab Md ◽  
Nabil A. Alhakamy ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Solid Lipid Nanoparticles ◽  
Human Breast Cancer ◽  
Lipid Nanoparticles ◽  
Dependent Manner ◽  
Human Breast ◽  
Solid Lipid ◽  
Receptor Modulation ◽  
Tamoxifen Citrate ◽  
Mcf 7

Breast cancer is conventionally treated by surgery, chemotherapy and radiation therapy followed by post operational hormonal therapy. Tamoxifen citrate is a best option to treat breast cancer because its selective estrogen receptor modulation activity. Owing to its antiestrogenic action on breast as well as uterine cells, Tamoxifen citrate shows uterine toxicity. The dose 20 mg per day of Tamoxifen citrate required to show therapeutic effect causes side effects and toxicity to vital organs such as liver, kidney and uterus. In the present study, transferrin-conjugated solid lipid nanoparticles (SLNs) were successfully prepared to enhance the active targeting of tamoxifen citrate in breast cancer. Developed formulations were evaluated for particle size, surface charge, surface morphology and in vitro dissolution studies. Developed formulations exhibited more cytotoxicity as compared to pure Tamoxifen citrate solution in time as well as concentration dependent manner on human breast cancer MCF-7 cells. Further, cell uptake and flow cytometry studies confirmed the qualitative uptake of developed D-SLN and SMD-SLN by human breast cancer MCF-7 cells. Overall, proposed study highlights that transferrin engineered nanocarriers could enhance the therapeutic response of nanomedicines for breast cancer treatment.

scholarly journals High anticancer efficacy of solid lipid nanoparticles containing Zataria multiflora essential oil against breast cancer and melanoma cell lines

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Alireza Valizadeh ◽  
Ali Asghar Khaleghi ◽  
Ghazaal Roozitalab ◽  
Mahmoud Osanloo
Keyword(s):  
Breast Cancer ◽  
Essential Oil ◽  
Solid Lipid Nanoparticles ◽  
Entrapment Efficiency ◽  
Lipid Nanoparticles ◽  
In Vivo Studies ◽  
Zataria Multiflora ◽  
Anticancer Efficacy ◽  
Solid Lipid

Abstract Background The cancer burden is rising rapidly worldwide, and it annually causes about 8.8 million deaths worldwide. Due to chemical drugs’ side effects and the emergence of resistance, the development of new green drugs has received much attention. We aimed to investigate whether solid-lipid nanoparticles containing essential oil of Zataria multiflora (ZMSLN) enhanced the anticancer efficacy of the essential oil against breast cancer (MDA-MB-468) and melanoma (A-375) cells. Results ZMSLN was prepared by the high-pressure homogenizer method; particle size 176 ± 8 nm, polydispersity index 0.22 ± 0.1, entrapment efficiency 67 ± 5%. The essential oil showed a dose-dependent antiproliferative effect on MDA-MB-468 and A-375 cells at all examined concentrations (75, 150, 300, 600, and 1200 μg/mL). Interestingly, after treating both cells with 75 μg/mL of ZMSLN, their viabilities were reduced to under 13%. Conclusion The finding showed that ZMSLN had a distinct antiproliferative efficacy; it could thus be considered a green anticancer candidate for further in vivo and in vivo studies.

scholarly journals Curcumin-Loaded Solid Lipid Nanoparticles Bypass P-Glycoprotein Mediated Doxorubicin Resistance in Triple Negative Breast Cancer Cells

Pharmaceutics ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 96 ◽  
Author(s):  
Gamal-Eldein Fathy Abd-Ellatef ◽  
Elena Gazzano ◽  
Daniela Chirio ◽  
Ahmed Ragab Hamed ◽  
Dimas Carolina Belisario ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Transcriptional Activation ◽  
Solid Lipid Nanoparticles ◽  
Plasma Membranes ◽  
Triple Negative ◽  
Lipid Nanoparticles ◽  
Solid Lipid ◽  
P Glycoprotein ◽  
Main Thing

Multidrug resistance (MDR) is a critical hindrance to the success of cancer chemotherapy. The main thing responsible for MDR phenotypes are plasma-membranes associated with adenosine triphosphate (ATP) Binding Cassette (ABC) drug efflux transporters, such as the P-glycoprotein (Pgp) transporter that has the broadest spectrum of substrates. Curcumin (CURC) is a Pgp inhibitor, but it is poorly soluble and bioavailable. To overcome these limitations, we validated the efficacy and safety of CURC, loaded in biocompatible solid lipid nanoparticles (SLNs), with or without chitosan coating, with the goal of increasing the stability, homogeneous water dispersibility, and cellular uptake. Both CURC-loaded SLNs were 5–10-fold more effective than free CURC in increasing the intracellular retention and toxicity of doxorubicin in Pgp-expressing triple negative breast cancer (TNBC). The effect was due to the decrease of intracellular reactive oxygen species, consequent inhibition of the Akt/IKKα-β/NF-kB axis, and reduced transcriptional activation of the Pgp promoter by p65/p50 NF-kB. CURC-loaded SLNs also effectively rescued the sensitivity to doxorubicin against drug-resistant TNBC tumors, without signs of systemic toxicity. These results suggest that the combination therapy, based on CURC-loaded SLNs and doxorubicin, is an effective and safe approach to overcome the Pgp-mediated chemoresistance in TNBC.

Sign in / Sign up

Export Citation Format

Share Document